Hypoparathyroidism - Pipeline Review, H1 2020
Hypoparathyroidism - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism – Pipeline Review, H1 2020, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.
Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 5 and 4 respectively.
Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism – Pipeline Review, H1 2020, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.
Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 5 and 4 respectively.
Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Aerami Therapeutics
Alize Pharma III SAS
Ascendis Pharma A/S
BridgeBio Pharma Inc
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Pharma
ProLynx LLC
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Hypoparathyroidism - Drug Profiles
ACP-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aerami-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-3601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
encaleret - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-6272K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
parathyroid hormone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCO-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem cell Therapy for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teriparatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
Apr 19, 2020: Ascendis Pharma announces top-line data from fixed dose portion of phase 2 trial demonstrating potential of TransCon PTH as a replacement therapy for Hypoparathyroidism
Nov 14, 2019: Ascendis Pharma expands TransCon PTH Phase 2 PaTH forward clinical trial to expedite enrollment of subjects previously treated with NATPARA in the United States
Oct 18, 2019: Leahy, Sanders, Welch urge FDA to swiftly resolve critical drug recall
Sep 23, 2019: Entera Bio reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with Hypoparathyroidism
Sep 06, 2019: Takeda Issues US Recall of NATPARA (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate
May 15, 2019: Takeda to highlight new research into the long-term complications of chronic hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting
Apr 24, 2019: Ascendis Pharma announces presentations related to TransCon PTH at upcoming Medical Conferences
Mar 26, 2019: Takeda presents new data at the Endocrine Society’s 2019 Annual Meeting about the patient burden and long-term impact of chronic hypoparathyroidism
Mar 26, 2019: Ascendis Pharma reports positive results from heiGHt trial
Mar 25, 2019: Ascendis Pharma announces results of study at ENDO 2019 evaluating impact of hypoparathyroidism on patient quality-of-life
Feb 12, 2019: Ascendis Pharma to study TransCon PTH for hypoparathyroidism
Nov 08, 2018: Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
Jun 06, 2018: Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
May 22, 2018: Shire Announces New Hypoparathyroidism Data at the 2018 European Congress of Endocrinology
May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Hypoparathyroidism - Overview
Hypoparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoparathyroidism - Companies Involved in Therapeutics Development
Aerami Therapeutics
Alize Pharma III SAS
Ascendis Pharma A/S
BridgeBio Pharma Inc
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Pharma
ProLynx LLC
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Hypoparathyroidism - Drug Profiles
ACP-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aerami-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-3601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
encaleret - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-6272K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
parathyroid hormone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PCO-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Agonize PTH1R for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIG-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem cell Therapy for Hypoparathyroidism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teriparatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoparathyroidism - Dormant Projects
Hypoparathyroidism - Product Development Milestones
Featured News & Press Releases
Apr 19, 2020: Ascendis Pharma announces top-line data from fixed dose portion of phase 2 trial demonstrating potential of TransCon PTH as a replacement therapy for Hypoparathyroidism
Nov 14, 2019: Ascendis Pharma expands TransCon PTH Phase 2 PaTH forward clinical trial to expedite enrollment of subjects previously treated with NATPARA in the United States
Oct 18, 2019: Leahy, Sanders, Welch urge FDA to swiftly resolve critical drug recall
Sep 23, 2019: Entera Bio reports positive results from a phase 2 PK/PD study of Oral PTH (1-34) in patients with Hypoparathyroidism
Sep 06, 2019: Takeda Issues US Recall of NATPARA (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate
May 15, 2019: Takeda to highlight new research into the long-term complications of chronic hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting
Apr 24, 2019: Ascendis Pharma announces presentations related to TransCon PTH at upcoming Medical Conferences
Mar 26, 2019: Takeda presents new data at the Endocrine Society’s 2019 Annual Meeting about the patient burden and long-term impact of chronic hypoparathyroidism
Mar 26, 2019: Ascendis Pharma reports positive results from heiGHt trial
Mar 25, 2019: Ascendis Pharma announces results of study at ENDO 2019 evaluating impact of hypoparathyroidism on patient quality-of-life
Feb 12, 2019: Ascendis Pharma to study TransCon PTH for hypoparathyroidism
Nov 08, 2018: Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
Jun 06, 2018: Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
May 22, 2018: Shire Announces New Hypoparathyroidism Data at the 2018 European Congress of Endocrinology
May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Hypoparathyroidism, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hypoparathyroidism - Pipeline by Aerami Therapeutics, H1 2020
Hypoparathyroidism - Pipeline by Alize Pharma III SAS, H1 2020
Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H1 2020
Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, H1 2020
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Hypoparathyroidism - Pipeline by Eli Lilly and Co, H1 2020
Hypoparathyroidism - Pipeline by Entera Bio Ltd, H1 2020
Hypoparathyroidism - Pipeline by Extend Biosciences Inc, H1 2020
Hypoparathyroidism - Pipeline by GC Pharma, H1 2020
Hypoparathyroidism - Pipeline by ProLynx LLC, H1 2020
Hypoparathyroidism - Pipeline by Sigilon Therapeutics Inc, H1 2020
Hypoparathyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Hypoparathyroidism - Dormant Projects, H1 2020
Number of Products under Development for Hypoparathyroidism, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hypoparathyroidism - Pipeline by Aerami Therapeutics, H1 2020
Hypoparathyroidism - Pipeline by Alize Pharma III SAS, H1 2020
Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H1 2020
Hypoparathyroidism - Pipeline by BridgeBio Pharma Inc, H1 2020
Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Hypoparathyroidism - Pipeline by Eli Lilly and Co, H1 2020
Hypoparathyroidism - Pipeline by Entera Bio Ltd, H1 2020
Hypoparathyroidism - Pipeline by Extend Biosciences Inc, H1 2020
Hypoparathyroidism - Pipeline by GC Pharma, H1 2020
Hypoparathyroidism - Pipeline by ProLynx LLC, H1 2020
Hypoparathyroidism - Pipeline by Sigilon Therapeutics Inc, H1 2020
Hypoparathyroidism - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Hypoparathyroidism - Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development for Hypoparathyroidism, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Aerami Therapeutics
Alize Pharma III SAS
Ascendis Pharma A/S
BridgeBio Pharma Inc
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Pharma
ProLynx LLC
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Number of Products under Development for Hypoparathyroidism, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Aerami Therapeutics
Alize Pharma III SAS
Ascendis Pharma A/S
BridgeBio Pharma Inc
Chugai Pharmaceutical Co Ltd
Eli Lilly and Co
Entera Bio Ltd
Extend Biosciences Inc
GC Pharma
ProLynx LLC
Sigilon Therapeutics Inc
Takeda Pharmaceutical Co Ltd
